Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Inclusion Criteria: * Male or female subject \>= 18 years; * Histologically or cytologically confirmed HER2-positive breast cancer defined as 3+ determined by validated IHC or positive by in situ hybridization (ISH); * Early-stage (T1c or 2, N1, M0; T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3, N2, M0; T3N1M0; T1c or 2 or 3, N3a or 3b, M0) breast cancer; * Adequate organ function assessed within 7 days prior to first trial treatment; * ECOG score 0 or 1; * Left ventricular ejection fraction (LVEF) ≥ 55% at baseline; Exclusion Criteria: * Stage IV (metastatic) breast cancer; * Inflammatory breast cancer; * Previous anti-cancer therapy or radiotherapy for any malignancy; * Major surgery for any reason within 28 days; * History of uncontrolled intercurrent illness; * Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance;